Thanks to artificial intelligence (AI) technology, an assistant decision-making system for cerebrovascular diseases was recently launched by Beijing Tian Tan Hospital and cooperative research institutions.

The system named “Tianze” can assist in diagnosis, treatment and prognosis of cerebral stroke, a common disease with a high reoccurrence rate of 17.1 percent one year after the first attack.

Furthermore, the recurrence rates in less developed areas are much higher, which adds difficulties for doctors in basic-level medical units.

Adopting big data and AI technologies, the “Tianze” system will determine what factors are associated with diseases with reference to the patient’s medical history and complications, and can offer a treatment solution after processing images of stroke patients.

It provides whole-process assistance that is conducive to clinical treatment, said Dr. Jing Jing from the neuroimaging research center of Beijing Tian Tan Hospital.

Today, the US, South Korea and European countries are developing AI products for adjuvant treatment, while China is taking its first steps in this field, said Wu Zhenzhou, technical director at an AI research center for neurological diseases.